...
首页> 外文期刊>British Journal of Clinical Pharmacology >Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics
【24h】

Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics

机译:父母的自身抑制性质,但不具有N-氧化物代谢物的性质有助于输注率依赖性的伏立康唑药代动力学

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aims The pharmacokinetics of voriconazole show a nonlinear dose–exposure relationship caused by inhibition of its own CYP3A‐dependent metabolism. Because the magnitude of autoinhibition also depends on voriconazole concentrations, infusion rate might modulate voriconazole exposure. The impact of four different infusion rates on voriconazole pharmacokinetics was investigated. Methods Twelve healthy participants received 100?mg voriconazole intravenous over 4?h, 400?mg over 6?h, 4?h, and 2?h in a crossover design. Oral midazolam (3?μg) was given at the end of infusion. Blood and urine samples were collected up to 48?h. Voriconazole and its N‐oxide metabolite were quantified using high‐performance liquid chromatography coupled to tandem mass spectrometry. Midazolam estimated metabolic clearance (eCLmet) was calculated using a limited sampling strategy. Voriconazole‐N‐oxide inhibition of cytochrome P450 (CYP) isoforms 2C19 and 3A4 were assessed with the P450‐Glo luminescence assay. Results Area under the concentration–time curve for 400?mg intravenous voriconazole was 16% (90% confidence interval: 12–20%) lower when administered over 6?h compared to 2?h infusion. Dose‐corrected area under the concentration–time curve for 100?mg over 4?h was 34% lower compared to 400?mg over 4?h. Midazolam eCLmet was 516?ml?min –1 (420–640) following 100?mg?4?h –1 voriconazole, 152?ml?min –1 (139–166) for 400?mg?6?h –1 , 192?ml?min –1 (167–220) for 400?mg?4?h ?1 , and 202?ml?min –1 (189–217) for 400?mg?2?h –1 . Concentration giving 50% CYP inhibition of voriconazole N‐oxide was 146?±?23?μmol?l –1 for CYP3A4, and 40.2?±?4.2?μmol?l –1 for CYP2C19. Conclusions Voriconazole pharmacokinetics is modulated by infusion rate, an autoinhibitory contribution voriconazole metabolism by CYP3A and 2C19 and to a lesser extent its main N‐oxide metabolite for CYP2C19. To avoid reduced exposure, the infusion rate should be 2?h.
机译:AIMS voriconazole的药代动力学显示出由其自身CYP3A依赖性代谢的抑制引起的非线性剂量暴露关系。由于自动抑制的幅度也取决于伏立康唑浓度,因此输注速率​​可能调节伏立康唑暴露。研究了四种不同输注率对伏立康唑药代动力学的影响。方法12种健康参与者收到100?Mg voriconazole静脉内超过4Ω·H,400毫克超过6Ω·毫克,400毫克,4Ω·H和2?H在交叉设计中。在输注结束时给出了口服咪达唑仑(3?μg)。收集血液和尿液样品,最高可达48℃。使用高性能液相色谱法定量旋转液相色谱法与串联质谱法定量伏立康唑及其N-氧化物代谢物。使用有限的取样策略计算咪达唑仑估计的代谢清除(Eclmet)。使用P450-Glo发光测定评估细胞色素P450(CYP)同种型2C19和3A4的voriconazole-n氧化物抑制。结果区域在400℃的浓度 - 时间曲线下静脉内伏立康唑为16%(90%置信区间:12-20%),当施用超过6Ωh时,施用超过6μl。浓度 - 时间曲线下的剂量矫正区域为100μmg,超过4Ω·h以上的400毫克为4μm,超过4Ω·h。 Midazolam Eclmet是516?ml?min -1(420-640)在100?mg?4?H -1 voriconazole之后,152毫升-1(139-166)400?mg?6?6?H -1, 192?ml?min -1(167-220)400?mg?4?h = 1,和202?ml?min -1(189-217)400?mg?2?h -1。浓度给予50%CYP抑制voriconazole n-氧化物的CYP3A4为146〜±23Ω·1-1,CYP2C19的40.2〜±4.2?μmol?1 -1。结论voriconazole药代动力学通过输注速率调节,CYP3A和2C19的自动抑制贡献voriconazole代谢和对CYP2C19的主要N-氧化物代谢物的较小程度。为了避免降低暴露,输液率应该是2?h。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号